This statistic depicts the market share of orphan drugs that cost patients more than 6,000 U.S. dollars in 2017. In that year, oncology drugs costing more than 6,000 dollars per patient annually accounted for nearly 41 percent of the total orphan drug market.
Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
IQVIA. (October 24, 2018). Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class [Graph]. In Statista. Retrieved December 22, 2024, from https://www.statista.com/statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
IQVIA. "Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class." Chart. October 24, 2018. Statista. Accessed December 22, 2024. https://www.statista.com/statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
IQVIA. (2018). Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class. Statista. Statista Inc.. Accessed: December 22, 2024. https://www.statista.com/statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
IQVIA. "Market Share of Orphan Drugs That Cost Patients More than $6,000 per Year in 2017, by Therapy Class." Statista, Statista Inc., 24 Oct 2018, https://www.statista.com/statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
IQVIA, Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class Statista, https://www.statista.com/statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/ (last visited December 22, 2024)
Market share of orphan drugs that cost patients more than $6,000 per year in 2017, by therapy class [Graph], IQVIA, October 24, 2018. [Online]. Available: https://www.statista.com/statistics/979287/market-share-of-orphan-drugs-more-expensive-than-6k-usd-by-therapy-class/
